Loading…
Loading…
HALB does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HALB and 80,000+ other tickers.
See exactly how HALB's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HALB and 80,000+ other tickers.
Halberd Corporation is a biotechnology firm dedicated to pioneering therapies for neurodegenerative conditions. The company's therapeutic focus encompasses a broad range of serious illnesses, including post-traumatic stress disorder (PTSD) and chronic traumatic encephalopathy (CTE), Alzheimer's disease, Parkinson's disease, various forms of cancer, and disorders impacting the blood and cerebrospinal fluid. Established in 2009, Halberd Corporation operates from its headquarters in Jackson Center, Pennsylvania.
Key Takeaways Jackson Center, PA, November 3, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Halberd Corporation (OTC: HALB), through its collaboration with scientists at Mississippi State University, continues work on a planned fourth quarter submission to the United States government seeking contractual funding for advanced animal research for the development
JACKSON CENTER, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB), through its collaboration with scientists at Mississippi State University, continues work on a planned fourth quarter submission to the United States government seeking contractual funding for advanced animal research for the development of an effective post-head-trauma treatment for Traumatic Brain Injury (TBI).
Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core Technologies Halberd Demonstrates NeuroSense AI FeasibilityHalberd Corporation successfully validated its NeuroSense AI system in a live demonstration, showcasing advanced multi-modal behavioral analysis technology designed to revolutionize traumatic brain injury (TBI) research and neurological diagnostics.
First-of-its-Kind Multi-Modal AI Platform Combines Advanced Behavioral Analysis with Claude AI to Accelerate Traumatic Brain Injury Recovery Monitoring, Among Other Medical Applications Jackson Center, PA, September 29, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) Halberd Corporation (OTC: HALB) today announced its acquisition of NeuroSense AI Corp.
JACKSON CENTER, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) today announced its acquisition of NeuroSense AI Corp., a groundbreaking artificial intelligence platform that will revolutionize behavioral analysis for traumatic brain injury (TBI) research and clinical assessment.